Hims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024. In the quarter to June 2026, revenue grew 38.3%, EPS fell 294.7%, free cash flow grew 5.09% and total debt rose 40.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow HIMS
Hims & Hers Health, Inc. (HIMS) EV/Sales
As of 16 October 2026, Hims & Hers Health, Inc. (HIMS) trades at a EV/Sales of 2.7×. Over the past ten years it has ranged from 0.0× (December 2020) to 11.9× (June 2021); the current reading is higher than 48% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.3× | (1.65%) |
| FY2024 | 3.3× | 61.56% |
| FY2023 | 2.1× | (2.60%) |
| FY2022 | 2.1× | (43.38%) |
| FY2022 | 3.7× | 3.81% |
| FY2021 | 3.6× | 18.10% |
| FY2021 | 3.1× | 9.18% |
| FY2020 | 2.8× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.3× | 58.49% |
| Mar 2026 | 2.1× | (36.13%) |
| Dec 2025 | 3.3× | (44.98%) |
| Sep 2025 | 6.0× | 9.02% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HIMS Hims & Hers Health, Inc. | 2.7× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 2.8× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.1× |
| LNTH Lantheus Holdings, Inc. compare | 4.2× |
| ALKS Alkermes plc compare | 4.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 6.6× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)